Visit statistics

May our host count your visit? It then sets a cookie and notes the pages you read, your device and your country. We see only totals. The site works the same either way. What is recorded

Peptides Explained

"Research use only": what the label means, and what it does not

In short

About 6 minutes for the short version; 8 with every detail open.

  • A "research use only" label is the seller's own words. It is not a licence or a check.
  • In EU law, what decides is how a product is sold and what it does.
  • In the US, the FDA looks at what the seller really intends, not only the label.
  • With such a product, nobody had to check what is in it, or how clean it is.
  • If you have one, read our pages on product risk and clean injecting.
Last reviewed
A pipette with eight thin tips puts pink liquid into a plastic plate with many small wells.
Lab research: a liquid goes into a test plate with many small wells. Photo: J.N. Eskra (Wikimedia Commons) CC BY-SA 4.0 Image details

Each section starts with the short answer. The rest is folded under “In detail”.

What does a 'research use only' label mean?

It is the seller’s own statement that a product is for lab work. It is not a licence.
Where the words come from, and what they do and do not tell you.
What we know
Where the wording comes fromIn US rules, “For Research Use Only” is a statement for lab test kits that are still being developed. It is not a category of medicine.1
How it is used on peptide vialsSellers put “research purposes only” or “not for human consumption” on vials of semaglutide, tirzepatide and other peptides that people inject.2,3
What it does not meanIt does not mean a regulator approved the product, checked its quality, or found it suitable to inject.4

A licensed medicine comes with a licence number, a leaflet and a maker who must answer for its quality. A “research” vial has none of these.4,5

Why the label does not decide what a product is

Does the label make the product legal in Europe?

No. EU law looks at how the product is sold as a whole, and at what it does.
How EU law decides whether a labelled product is a medicine, step by step.
  1. Two tests. A product is a medicine if it is presented as treating or preventing disease, or if it can change body functions through a drug-like effect.4
  2. Presentation is more than the label. What counts is the impression an ordinary, well-informed person gets. Labels, leaflets and what is said all count, and so does what is only hinted at.6
  3. The form is a clue too. The EU court said the form of a product can be strong evidence of what the seller intends.6
  4. Function depends on the substance. If a substance can change body functions in a way that really matters, the label does not change that.7
  5. In doubt, medicines law wins. A product that could be a medicine and also something else is treated as a medicine, once its medicine status is shown.4,7

Belgium’s medicines agency says the same in plain words. If a product contains a pharmacologically active substance, or is presented as a medicine, it is a medicine. That it is sold elsewhere as something else “is not a valid argument”.8

In detail Where the law is less clear

We found no EU court ruling about “research use only” labels as such. The rulings above set general tests, and authorities apply them case by case.9

The “function” test has a limit. A product is a medicine by function only if science shows it can change body functions in a way that really matters.7 The EU court has also said this test covers substances that can benefit health, not substances taken only to get high.9 For a peptide tested only in animals, this can be argued about.

That is why the “presentation” test often decides such cases. A website that promises healing, fat loss or muscle can be enough. A vial made for injecting is a strong clue, but not proof on its own.6 This is our reading of the rulings, not a court decision about any one product. Our legal reviewer will check it.

The United States: what the seller intends

Does the label protect sellers in the US?

No. The FDA looks at what the seller really intends, shown by all their words and actions.
How the US medicines agency decides what a product is for.
  1. Intended use decides. In US rules, the use a product is meant for is judged from the seller’s real, “objective” intent.10
  2. Everything counts as evidence. Labels, adverts, what the seller says, and how the product is sold. Even a use the seller knows about but does not advertise can count.10
  3. The FDA has applied this to peptide sellers. It sent them warning letters from 2024 to 2026. A “research use only” statement does not stop a product being a drug, it said. What counts is that the seller’s website shows it is meant for people.3
  4. The result. The FDA calls such products unapproved new drugs. Selling them across state lines breaks federal law.3

More on US law: United States.

In detail What the FDA's letters to peptide sellers say

In its warning letters, the FDA quotes the sellers’ own “research use only” and “not for human consumption” statements. It then sets them against the health claims on the sellers’ own websites. Its conclusion: the website shows the products are meant as drugs for people, so they are unapproved new drugs.3 In one letter from August 2026, the FDA said that bacteriostatic water sold to prepare such products is itself a drug.3

What the label changes in each country

Is it legal for me to buy a research-labelled peptide?

The label changes nothing. What happens to a buyer differs by country.
The label does not make an unlicensed peptide legal to sell or to send. The Netherlands, Belgium and the United States, checked on 22 October 2026.
NetherlandsBelgiumUnited States
Does the label make it legal to sell?No Selling a medicine without a licence is forbidden.11No A licence is needed.12No The FDA treats such products as unapproved drugs.3
Can a parcel sent to you be stopped?Yes Customs and the IGJ seize and destroy parcels with illegal medicines.13,14Yes The FAMHP seizes them.8Yes The FDA can refuse a personal import.15
Is a fine likely for a first parcel?Unknown Not known. The enforcement we found targets sellers.16,17No The first time, a warning.8Unknown Not covered by the sources we checked.15

See the Netherlands and Belgium for the detail.

What the label means for you

What does it mean for me if my product has this label?

Nobody had to check what is in it, how clean it is, or how it was made.
A licensed medicine comes with checks. A research-labelled vial comes with none that anyone must do. What EU law requires of a licensed medicine, against what is known about products sold as 'research only'.
Licensed medicine from a pharmacyProduct labelled “research use only”
Made under medicine quality rules (GMP)?Yes The maker must follow GMP and use active substances made under GMP.4Unknown No one has to. You cannot tell from the vial.18
Made under the rules for sterile products?Yes Injections must follow the EU rules for sterile production.19Unknown Unknown. In one lab test of three vials, sterility was not tested.20
Does the amount match the label?Yes Checked as part of the licence and batch release.4Unknown In that test, from about half to almost double the label.20
Must someone collect and report side effects?Yes The licence holder must run a system for this.4No No one has that duty. You can still report to Lareb or the FAMHP.21,22
Comes with a leaflet about warnings and interactions?Yes An official leaflet and product information.4No There is no official leaflet.4

The amount in a vial may not match the label

51% to 190%

of the amount on the label, in three vials sold as retatrutide

What was counted Three products sold as retatrutide in Australia, tested in an accredited lab (Piatkowski 2026); sterility and endotoxin were not tested Source Piatkowski et al. (2026)20

If your product did not come from a pharmacy, these are practical next steps:

Sources 20, 18, 22

In detail The lab test of three vials, in more detail

In 2026, researchers at the University of Queensland reported on three products sold as retatrutide in Australia. They were sent in anonymously to a drug-checking service and tested in an accredited lab. All three contained retatrutide. But the amount ranged from 51% to 190% of what the label said. Lead and other metals were found only at low levels. Sterility and endotoxin, a toxic part of some bacteria, were not tested. Three samples cannot show how common these problems are.20

In detail Why sellers use the label, and what it costs you

Three pharmacists wrote an editorial about online sales of semaglutide and tirzepatide “for research purposes”. They describe what the label does. It lets buyers skip the prescriber and the pharmacist. That makes it hard to spot risky drug combinations, or to check on the person afterwards. Quality standards may not be met.2

A doctor can still help you with those checks. See talking to your doctor.

Sources

Every claim on this page links to one of these sources. Scholarly sources link to their DOI; regulatory sources to the regulator's own page.

In detail All 22 sources, numbered as in the text
  1. U.S. Food and Drug Administration (Electronic Code of Federal Regulations) (2026). 21 CFR 809.10 – Labeling for in vitro diagnostic products. eCFR. Law ecfr.gov — accessed 22 October 2026 ↩
  2. Belcourt J, Ly P, White CM (2025). Bypassing prescribers and pharmacists: online purchasing of semaglutide and tirzepatide "for research purposes". Annals of Pharmacotherapy 59:485-490. Research article doi:10.1177/10600280241277551 ↩
  3. U.S. Food and Drug Administration (2026). Warning Letters (searchable database). Regulator fda.gov — accessed 22 October 2026 ↩
  4. European Parliament and Council of the European Union (2001). Directive 2001/83/EC on the Community code relating to medicinal products for human use (consolidated text). Official Journal of the European Communities, L 311. Law eur-lex.europa.eu — accessed 20 October 2026 ↩
  5. Inspectie Gezondheidszorg en Jeugd (IGJ) (2026). Vragen over afleveren geneesmiddelen zonder handelsvergunning. Regulator igj.nl — accessed 22 October 2026 ↩
  6. Court of Justice of the European Communities (Fifth Chamber) (1983). Judgment of 30 November 1983, Criminal proceedings against Leendert van Bennekom, Case 227/82. EUR-Lex (CELEX 61982CJ0227). Law eur-lex.europa.eu — accessed 22 October 2026 ↩
  7. Court of Justice of the European Communities (First Chamber) (2009). Judgment of 15 January 2009, Hecht-Pharma GmbH v Staatliches Gewerbeaufsichtsamt Lüneburg, Case C-140/07. EUR-Lex (CELEX 62007CJ0140). Law eur-lex.europa.eu — accessed 22 October 2026 ↩
  8. Federal Agency for Medicines and Health Products (FAMHP / FAGG / AFMPS) (2024). Questions and answers on seizure of postal packages due to illegal importation of medicinal products or importation of non-compliant medical devices. Regulator famhp.be — accessed 22 October 2026 ↩
  9. Court of Justice of the European Union (Fourth Chamber) (2014). Judgment of 10 July 2014, Criminal proceedings against Markus D. and G., Joined Cases C-358/13 and C-181/14. EUR-Lex (CELEX 62013CJ0358). Law eur-lex.europa.eu — accessed 22 October 2026 ↩
  10. U.S. Food and Drug Administration (Electronic Code of Federal Regulations) (2026). 21 CFR 201.128 – Meaning of 'intended uses'. eCFR. Law ecfr.gov — accessed 22 October 2026 ↩
  11. Staten-Generaal / Koninkrijk der Nederlanden (2007). Geneesmiddelenwet, artikel 40 (verbod op geneesmiddelen zonder handelsvergunning, en de uitzonderingen). wetten.overheid.nl (BWBR0021505), version in force from 9 September 2025. Law wetten.overheid.nl — accessed 22 October 2026 ↩
  12. Belgische Staat / État belge (1964). Wet van 25 maart 1964 op de geneesmiddelen voor menselijk gebruik, artikel 6 § 1 (vergunning voor het in de handel brengen vereist). ejustice.just.fgov.be. Law ejustice.just.fgov.be — accessed 20 October 2026 ↩
  13. Inspectie Gezondheidszorg en Jeugd (IGJ) (2025). Operatie SHIELD: IGJ en Douane nemen 60.000 pillen in beslag. Regulator igj.nl — accessed 22 October 2026 ↩
  14. Staten-Generaal / Koninkrijk der Nederlanden (2007). Geneesmiddelenwet, artikel 115 (inbeslagname en bevelen). wetten.overheid.nl (BWBR0021505), version in force from 9 September 2025. Law wetten.overheid.nl — accessed 22 October 2026 ↩
  15. U.S. Food and Drug Administration (2025). Personal Importation. Regulator fda.gov — accessed 22 October 2026 ↩
  16. Inspectie Gezondheidszorg en Jeugd (IGJ) (2023). Toezicht op online medicijnen. Regulator igj.nl — accessed 22 October 2026 ↩
  17. Inspectie Gezondheidszorg en Jeugd (IGJ) (2025). Inspectie maakt zich zorgen over toename van online-nepapotheken. Regulator igj.nl — accessed 22 October 2026 ↩
  18. Inspectie Gezondheidszorg en Jeugd (IGJ) (2026). Online medicijnen. Regulator igj.nl — accessed 22 October 2026 ↩
  19. European Commission, Directorate-General for Health and Food Safety (2026). EudraLex – Volume 4 – Good Manufacturing Practice (GMP) guidelines. Regulator health.ec.europa.eu — accessed 22 October 2026 ↩
  20. Piatkowski T, Craven A, Cornell S, Ferris J (2026). Composition and Labelling Accuracy of Products Sold as Retatrutide in Australia. Drug and Alcohol Review 45:e70231. Research article doi:10.1111/dar.70231 ↩
  21. Bijwerkingencentrum Lareb (2026). Alles over bijwerkingen melden. Web page lareb.nl — accessed 20 October 2026 ↩
  22. Federal Agency for Medicines and Health Products (FAMHP / FAGG / AFMPS) (2023). Questions and answers regarding reporting adverse reactions. Regulator famhp.be — accessed 22 October 2026 ↩